Abstract
Rationale: Native glucagon-like peptide (GLP)-2 as well as GLP-2 analogs have been shown to improve intestinal function in patients with short bowel syndrome (SBS). Since the effects of GLP-2 on endogenous meal-stimulated intestinal hormone release and glucose homeostasis are largely unknown, we aimed to elucidate these relationships in patients with SBS treated with glepaglutide, a long-acting GLP-2 analog.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
